NVO Jan 2026 67.500 call
| Previous close | 69.17 |
| Open | 69.17 |
| Bid | 63.75 |
| Ask | 66.15 |
| Strike | 67.50 |
| Expiry date | 2026-01-16 |
| Day's range | 69.17 - 69.17 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
- Reuters
UPDATE 1-Novo Nordisk owner to invest $200 million in quantum computing startups
Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk, said on Wednesday it planned to invest around $200 million in quantum computing startups. The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic. Academics and industry analysts say quantum computing may prove to be among the most transformational technological developments of the 21st century.
- Reuters
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish Medicines Agency said on Wednesday. In 2023, 50% of new patients suffering from type 2 diabetes began treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first, the Medicines Agency said. Demand for Novo Nordisk's diabetes drug Ozempic has soared as many people have started using the diabetes drug for its weight-loss effects.
